UK markets closed
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • FTSE 250

    20,338.96
    +93.53 (+0.46%)
     
  • AIM

    933.20
    +4.84 (+0.52%)
     
  • GBP/EUR

    1.1820
    +0.0002 (+0.02%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • BTC-GBP

    20,322.74
    +497.81 (+2.51%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • DOW

    33,761.05
    +424.38 (+1.27%)
     
  • CRUDE OIL

    91.88
    -2.46 (-2.61%)
     
  • GOLD FUTURES

    1,818.90
    +11.70 (+0.65%)
     
  • NIKKEI 225

    28,546.98
    +727.65 (+2.62%)
     
  • HANG SENG

    20,175.62
    +93.19 (+0.46%)
     
  • DAX

    13,795.85
    +101.34 (+0.74%)
     
  • CAC 40

    6,553.86
    +9.19 (+0.14%)
     

COPD Epidemiology Analysis 2018-2020 and Forecasts 2021-2030 for the US, Germany, France, Italy, Spain, UK and Japan

·4-min read

Dublin, Dec. 02, 2021 (GLOBE NEWSWIRE) -- The "Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Gender-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Age-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation, and Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

Detailed Epidemiology Segmentation

  • The total diagnosed prevalent population of Chronic Obstructive Pulmonary Disease (COPD) in seven major markets was found to be 31,730,590 in 2020 and is anticipated to increase in 2030.

  • The estimates suggest a higher diagnosed prevalence of COPD in the United States with 17,455,605 diagnosed cases in 2020, which might increase in 2030.

  • The majority of cases of Chronic Obstructive Pulmonary Disease (COPD) are female as compared to male, in the US. But in EU-5 and Japan the diagnosed cases of males represents majority of the cases.

  • In the epidemiology model of Chronic Obstructive Pulmonary Disease (COPD), there are multiple age groups referred ranging from 18-44 years, 45-54 years, 55-64 years, 64-74 years, and 75+ years, for COPD in the US. The highest was 4,601,558 in the age group 55-64 years, in 2020.

  • In 2020, the US had 2,967,453, 8,727,802, 4,538,457 and 1,221,892 cases of GOLD 1, GOLD 2, GOLD 3, and GOLD 4.

Scope of the Report

  • The report covers the descriptive overview of Chronic Obstructive Pulmonary Disease (COPD), explaining its causes, symptoms, pathophysiology, and genetic basis.

  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • The report assesses the disease risk and burden and highlights the unmet needs of Chronic Obstructive Pulmonary Disease (COPD).

  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

  • The report provides the segmentation of the disease epidemiology for 7MM Total Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Gender-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Age-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation, and Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History.

Report Highlights

  • 10-Year Forecast of Chronic Obstructive Pulmonary Disease (COPD)

  • 7MM Coverage

  • Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD)

  • Gender-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD)

  • Age-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD)

  • Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation

  • Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History

Key Questions Answered

  • What are the disease risk, and burden of Chronic Obstructive Pulmonary Disease (COPD)?

  • What is the historical Chronic Obstructive Pulmonary Disease (COPD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?

  • What would be the forecasted patient pool of Chronic Obstructive Pulmonary Disease (COPD) at the 7MM level?

  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Chronic Obstructive Pulmonary Disease (COPD)?

  • Out of the above-mentioned countries, which country would have the highest prevalent population of Chronic Obstructive Pulmonary Disease (COPD) during the forecast period (2021-2030)?

  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?

For more information about this report visit https://www.researchandmarkets.com/r/xjjqv3

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting